SCHEMBL984927

SCHEMBL984927

O=C1CCNC2=CC=CCC12

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7362923 0.89 OR51E2 (0.33)
SCHEMBL27841594 0.81
SCHEMBL7368994 0.76 CRBN (0.34) CRBN
SCHEMBL8300820 0.72
SCHEMBL3495824 0.70
SCHEMBL8614102 0.70
SCHEMBL5445329 0.69
SCHEMBL27372776 0.68 TLR4 (0.33)
SCHEMBL11428684 0.68
SCHEMBL7522462 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291355-A2 NOVEL TETRAHYDROQUINOLINES AS AROMATASE INHIBITORS Panjab University (IN) 2011-03-09 EP claimed
WO-2009087684-A2 NOVEL TETRAHYDROQUINOLINES AS AROMATASE INHIBITORS PANJAB UNIVERSITY (IN) 2009-07-16 WO claimed
EP-3394032-A1 COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES The University of Chicago (US) 2018-10-31 EP disclosed
WO-2017112678-A1 COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES MCLEOD RIMA (US) 2017-06-29 WO disclosed
EP-2632923-B1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-14 EP disclosed
EP-1941881-B1 Naphthalene derivatives for the treatment of dermatitis and psoriasis MITSUBISHI TANABE PHARMA CORP (JP) 2014-08-13 EP disclosed
EP-2632923-A1 QUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2013-09-04 EP disclosed
WO-2012055466-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-05-03 WO disclosed
US-8084611-B2 Process for preparing tetrahydroquinoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-12-27 US disclosed
EP-2007728-B1 A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORP (JP) 2011-11-16 EP disclosed
WO-2011131370-A1 MELT-GRANULATED FINGOLIMOD RATIOPHARM GMBH (DE) 2011-10-27 WO disclosed
WO-2003054000-A1 TEMPLATE-FIXED PEPTIDOMIMETICSAS INHIBITORS OF SERINE PROTEASES POLYPHOR LTD. (CH) 2003-07-03 WO disclosed
US-6452032-B1 ANTAGONISTS, AGONISTS, OR INVERSE AGONISTS PARTICULARLY FOR RETINOID AND FARNESOID RECEPTORS; REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION AND OF LIPID METABOLISM; DERMATOSES SUCH AS ACNE, PSORIASIS, ICTHYOSIS AND ECZEMA ALLERGAN SALES, LLC 2002-09-17 US disclosed
WO-2002070547-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY POLYPHOR LTD. (CH) 2002-09-12 WO disclosed
EP-1185277-A1 METHODS FOR MODULATING FXR RECEPTOR ACTIVITY Allergan Sales, Inc. (US) 2002-03-13 EP disclosed
EP-1185539-A1 ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY Allergan Sales, Inc. (US) 2002-03-13 EP disclosed
WO-2000076523-A1 METHODS FOR MODULATING FXR RECEPTOR ACTIVITY ALLERGAN SALES, INC. (US) 2000-12-21 WO disclosed
WO-2000077011-A1 ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY ALLERGAN SALES, INC. (US) 2000-12-21 WO disclosed
US-5710150-A ARGININE VASOPRESSIN ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-01-20 US disclosed
EP-0716083-A1 BENZAZEPINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE FOR THE SAME YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-06-12 EP disclosed